Malaria vaccines are an area of intensive research. Emergence of artemisinin and multi-drug resistant strains of especially P. falciparum are driving research. Current approaches are focusing on recombinant protein and attenuated whole organism vaccines. Various vaccines have reached the state of clinical trials; most demonstrated insufficient immunogenicity.
The clinical testing of RTS,S/AS01 is at least 5-10 years ahead of other candidate malaria vaccines. RTS,S/AS01 is a vaccine against Plasmodium falciparum, with no protection against P. vivax malaria. Vaccines currently licensed are against human diseases caused by either viruses or bacteria.
Related journals for Malaria vaccines
Advances in biology and medicine, clinical trials, emerging infectious diseases .